Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical neuropharmacology

• Publication date

  2013-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/WNF.0b013e318279bcfaPMID 23334069
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for Alzheimer's disease.

  2013cited by this paper
• A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

  2010cited by this paper
• β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia

  2010cited by this paper
• Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease

  2010cited by this paper
• Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease.

  2009cited by this paper
• Evaluation of the Usability of a Brief Computerized Cognitive Screening Test in Older People for Epidemiological Studies

  2009cited by this paper
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

  2009cited by this paper
• Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

  2009influential reference
• Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

  2006cited by this paper
• Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice

  2006cited by this paper
• Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

  2004cited by this paper
• Immunotherapy for Alzheimer's disease

  2004cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper

• Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer's Treatment.

  2025cites this paper
• Treating Alzheimer’s Disease: Focusing on Neurodegenerative Consequences

  2024cites this paper
• Targets, trials and tribulations in Alzheimer therapeutics.

  2023cites this paper
• Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases.

  2023cites this paper
• Overview of therapeutic targets in management of dementia.

  2022cites this paper
• USING FOR ELECTRONIC PROOF CORRECTION

  2022cites this paper
• Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives

  2022cites this paper
• Therapy for Alzheimer's disease: Missing Targets and Functional Markers?

  2021cites this paper
• Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials

  2021cites this paper
• Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease a systematic review.

  2021cites this paper
• Brain metastasis models: What should we aim to achieve better treatments?

  2020cites this paper
• Immunotherapy Targeting Amyloid-β Peptides in Alzheimer’s Disease

  2020cites this paper
• Polymeric Nanoparticles for Nasal Drug Delivery to the Brain: Relevance to Alzheimer's Disease

  2020cites this paper
• Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

  2019influential citation
• Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)

  2019cites this paper
• Spectrum of Pharmacological Activity of Monoclonal Antibodies

  2019cites this paper
• New treatment modalities in Alzheimer's disease

  2019cites this paper
• Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?

  2019cites this paper
• Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

  2018cites this paper
• Alzheimer’s disease hypothesis and related therapies

  2018cites this paper
• Computational Approaches for Therapeutic Application of Natural Products in Alzheimer’s Disease

  2018cites this paper
• Passive Aβ Immunotherapy: Current Achievements and Future Perspectives

  2018cites this paper
• Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease.

  2018cites this paper
• The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice

  2017cites this paper
• Ex vivo18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

  2017cites this paper
• Antibody Therapeutics Targeting Aβ and Tau.

  2017cites this paper
• Can the retina be used to diagnose and plot the progression of Alzheimer's disease?

  2017cites this paper
• The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer’s disease clinical trials

  2017cites this paper
• Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

  2017cites this paper
• Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

  2017cites this paper
• Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise

  2017cites this paper
• Dosage de phagocytose à médiation cellulaire dépendante des anticorps pour mesurer de façon fiable l'absorption de protéines agrégées

  2017cites this paper
• RECENT ADVANCES IN ALZHEIMER'S DISEASE: CAUSES AND TREATMENT

  2016cites this paper
• Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?

  2016cites this paper
• Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products

  2016cites this paper
• Immunotherapy Against Amyloid-β in Alzheimer’s Disease: An Overview

  2016cites this paper
• A Review on Current Strategies and Future Perspective in Respect to Alzheimer's Disease Treatment

  2016cites this paper
• A cure for Alzheimer ’ s disease ?

  2016influential citation
• Antibody Approaches To Treat Brain Diseases

  2016cites this paper
• New developments of clinical trial in immunotherapy for Alzheimer's disease.

  2015cites this paper
• Frontiers in Clinical Drug Research - Alzheimer Disorders

  2015cites this paper
• Diabetes Associated Memory Impairment: Perspective on Management Strategies

  2015cites this paper
• Expediting the Discovery and Potential Translation of Theranostic Agents for Alzheimer's Disease

  2015cites this paper
• Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

  2015cites this paper
• Cerebral Amyloid Angiopathy: Emerging Concepts

  2015cites this paper
• Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

  2015cites this paper
• Immunotherapy for Alzheimer’s disease: past, present and future

  2014cites this paper
• Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

  2014cites this paper
• Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

  2014cites this paper
• C URRENT OPINION Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

  2014cites this paper
• Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

  2014cites this paper
• Imaging endpoints for clinical trials in Alzheimer’s disease

  2014cites this paper
• Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease

  2013cites this paper
• Biomarker utility in Alzheimer's disease clinical trials

  2013cites this paper
• Krankheitsmodifizierende Behandlungen

  2013cites this paper
• New treatment strategies for Alzheimer's disease: is there a hope?

  2013cites this paper
• Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.

  2013cites this paper